chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Arm  soreness; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Arm  soreness) in an 86-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced ARTHRALGIA (Arm  soreness). At the time of the report, ARTHRALGIA (Arm  soreness) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided. Vaccine was administered in his shoulder and he read that it was supposed to be in his muscle.
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Vasculitis
Clinical narrative: Arms, legs, hands, feet, face and neck all became red; Capillaries became inflamed and expanded; A spontaneous report was received from a consumer, concerning a 57-year-old female patient, who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced erythema and vasculitis.    The patient's medical history was not provided.  Concomitant product use was not provided by the reporter.       On 28 Jan 2021, approximately 8 days prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Batch number: 029L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.    On 04 Feb 2021, after receiving vaccine patient experienced systemic inflammatory response where her "arms, legs, hands, feet, face and neck all became red, the capillaries became inflamed and expanded". Treatment for the event included Zyrtec, but it has not helped.     Action taken with mRNA-1273 in response to the events were not provided.  The outcome of the events were not resolved at the time of this report.; Reporter's Comments: This case concerns a 57 year old, female patient, who experienced a non-serious unexpected event of Erythema and vasculitis after receiving mRNA-1273 (Lot# 029L20A). Very limited information regarding this event has been provided at this time. Further information has been requested
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Conjunctival scar, Eye swelling, Iritis, Ocular hyperaemia, Vitreous floaters
Clinical narrative: Iritis; Scarring in the back of eye; Floaters in both eyes; eyes red inside; eyes swollen outside; This spontaneous case was reported by a consumer and describes the occurrence of IRITIS (Iritis), CONJUNCTIVAL SCAR (Scarring in the back of eye), VITREOUS FLOATERS (Floaters in both eyes), OCULAR HYPERAEMIA (eyes red inside) and EYE SWELLING (eyes swollen outside) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced IRITIS (Iritis), CONJUNCTIVAL SCAR (Scarring in the back of eye), VITREOUS FLOATERS (Floaters in both eyes), OCULAR HYPERAEMIA (eyes red inside) and EYE SWELLING (eyes swollen outside). The patient was treated with PREDNISONE at an unspecified dose and frequency and ATROPINE at an unspecified dose and frequency. At the time of the report, IRITIS (Iritis), CONJUNCTIVAL SCAR (Scarring in the back of eye), VITREOUS FLOATERS (Floaters in both eyes), OCULAR HYPERAEMIA (eyes red inside) and EYE SWELLING (eyes swollen outside) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site mass
Clinical narrative: Still where the injection site was I have a bump and its still red; Still where the injection site was I have a bump and its still red; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE MASS (Still where the injection site was I have a bump and its still red) and INJECTION SITE ERYTHEMA (Still where the injection site was I have a bump and its still red) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunization.     No Medical History information was reported.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced INJECTION SITE MASS (Still where the injection site was I have a bump and its still red) and INJECTION SITE ERYTHEMA (Still where the injection site was I have a bump and its still red). At the time of the report, INJECTION SITE MASS (Still where the injection site was I have a bump and its still red) and INJECTION SITE ERYTHEMA (Still where the injection site was I have a bump and its still red) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.  No concomitant medications reported.  No treatment information provided.
Sex: F
Vaccine: COVID19
Symptoms: Product colour issue
Clinical narrative: second dose of the vaccine was brownish color in the syringe and darker; A spontaneous report was received from a consumer who was also a female patient of unreported age, who received Moderna's COVID-19 vaccine (mRNA-1273) and states that her first dose of the vaccine was white/off white in color and the second dose was brownish and darker/product color variation.   The patient's medical history was not provided.  Products known to have been used by the patient were not provided.  On an unreported date, the patient received the first of two planned doses of mRNA-1273 (Lot number: unknown) for prophylaxis of COVID-19 infection.  Patient reports the liquid in the syringe was white to off-white.  Upon receiving the second dose, on  another unknown date, the patient received the second of two planned doses of mRNA-1273 (Lot number: unknown) for prophylaxis of COVID-19 infection.   The patient noticed that the second dose of the vaccine was brownish and darker in the syringe than the first dose.  Consent to contact was denied.  Treatment information was not provided.   Action taken with mRNA-1273 was not applicable.  The outcome of the events, the second dose was brownish and darker/produce color variation, was considered resolved.; Reporter's Comments: This report refers to a case of product color issue for mRNA-1273 (lot # unknown) with no associated AEs reported.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site movement impairment, Vaccination site pain
Clinical narrative: limited mobility; pain from top of shoulder all the way down arm; This spontaneous case was reported by an other health professional and describes the occurrence of VACCINATION SITE MOVEMENT IMPAIRMENT (limited mobility) and VACCINATION SITE PAIN (pain from top of shoulder all the way down arm) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 39K20A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: pneumonia vaccine shot. Concurrent medical conditions included Penicillin allergy (Augmentin) and Allergy to nuts (Pine Nuts). Concomitant products included LEVOTHYROXINE for Hypothyroidism.   On 16-Jan-2021 at 3:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021 at 2:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (pain from top of shoulder all the way down arm). On 16-Feb-2021, the patient experienced VACCINATION SITE MOVEMENT IMPAIRMENT (limited mobility). The patient was treated with PARACETAMOL (TYLENOL) for Pain, at an unspecified dose and frequency and Immobilization for Vaccination site pain. On 12-Feb-2021 at 12:00 PM, VACCINATION SITE PAIN (pain from top of shoulder all the way down arm) had resolved. On 19-Feb-2021, VACCINATION SITE MOVEMENT IMPAIRMENT (limited mobility) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient was treated with acetaminophen, ice, and an arm sling. Patient has experienced similar event (arm limited mobility) with pneumonia vaccine shot.  patient took  tylenol which helped with the pain but did not make it mobile. she used ice on and off and after 3 days It got use of it back..   Most recent FOLLOW-UP information incorporated above includes: On 02-Apr-2021: Follow-up information received on 2-apr-2021 contains suspect drug dose one, concomitant and treatment details.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy, Glucose tolerance test, Pregnancy test
Clinical narrative: Pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnancy) in a 30-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011J20A and 039K20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (one drink per day) on 12-Jun-2020. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) from 12-Jun-2021 to an unknown date for an unknown indication.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 07-Nov-2020 and the estimated date of delivery was 14-Aug-2021. On 08-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (Pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  ninth week of the pregnancy.  On 08-Jan-2021, EXPOSURE DURING PREGNANCY (Pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Dec-2020, Pregnancy test: positive (Positive) positive. On 26-May-2021, Glucose tolerance test: normal (normal) normal.         Patient's estimated date of conception was reported as 19-NOV-2020. Treatment medications were unknown.   Most recent FOLLOW-UP information incorporated above includes: On 01-Jun-2021: Added patient demographics, LMP date, Due date, Medical history, Lab data, Dose1 and 2 details, concomitant medication. This case was received for pregnancy data clean up, but at level it was observed that FU 1 was not processed . hence FU 1 information is added now into this case as well as changes were made in pregnancy data field.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Exposure during pregnancy, Headache, Myalgia
Clinical narrative: dizzy spells; Muscle aches; Headaches; 4 months pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (4 months pregnant), DIZZINESS (dizzy spells), MYALGIA (Muscle aches) and HEADACHE (Headaches) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (4 months pregnant), DIZZINESS (dizzy spells), MYALGIA (Muscle aches) and HEADACHE (Headaches). At the time of the report, EXPOSURE DURING PREGNANCY (4 months pregnant) had resolved and DIZZINESS (dizzy spells), MYALGIA (Muscle aches) and HEADACHE (Headaches) outcome was unknown.            No relevant concomitant medication was reported. Treatment information was not provided. Patient is 4 months pregnant.; Sender's Comments: This is a case of product exposure during pregnancy with associated AEs for this 28-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy. Based on the current available information and temporal association between the use of the product and the start date of the events other than the exposure during pregnancy, a causal relationship cannot be excluded
Sex: U
Vaccine: COVID19
Symptoms: Poor quality product administered, Product storage error
Clinical narrative: Patient received one dose of moderna vaccine from a vial that was out of temperature control; Patient received one dose of moderna vaccine from a vial that was out of temperature control; A spontaneous report received from a consumer of unknown age and gender. Patient  received dose of Moderna COVID-19 vaccine and said the vial was out of temperature control.    The patient's medical history was not included. Patient's concomitant medication was not included.    On 10 Feb 2021, the patient received their first of two planned doses of mRNA-1273 unknown arm (Batch number: unknown) intramuscularly for prophylaxis of COVID-19 infection.   Patient stated they received one dose of Moderna COVID-19 vaccine from a vial that was out of temperature control.  Treatment information was not provided/ unknown.  Action taken with mRNA-1273 in response to the event was not provided/unknown.   The outcome of the event was resolved on 10 Feb 2021.; Reporter's Comments: This report refers to a case of "Product storage error" and "Out of specification product use" for mRNA-1273, lot # unknown with no associated adverse events.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose, Fatigue, Headache, Hyperglycaemia
Clinical narrative: Blood sugar started to rise /noticed that the sugar was high and previous to the vaccine was low/since the shot was the blood sugar was 200 and high as 300/it's making the blood sugar very high; Headache; Tired; This spontaneous case was reported by a consumer and describes the occurrence of HYPERGLYCAEMIA (Blood sugar started to rise /noticed that the sugar was high and previous to the vaccine was low/since the shot was the blood sugar was 200 and high as 300/it's making the blood sugar very high), HEADACHE (Headache) and FATIGUE (Tired) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A or 030L2CA) for COVID-19 vaccination.   Concurrent medical conditions included Diabetes (insulin dependent) and Hypertension. Concomitant products included INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY) and INSULIN LISPRO (LISPRO INSULIN) for Diabetes.  On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, the patient experienced HYPERGLYCAEMIA (Blood sugar started to rise /noticed that the sugar was high and previous to the vaccine was low/since the shot was the blood sugar was 200 and high as 300/it's making the blood sugar very high), HEADACHE (Headache) and FATIGUE (Tired). At the time of the report, HYPERGLYCAEMIA (Blood sugar started to rise /noticed that the sugar was high and previous to the vaccine was low/since the shot was the blood sugar was 200 and high as 300/it's making the blood sugar very high), HEADACHE (Headache) and FATIGUE (Tired) outcome was unknown.   DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Feb-2021, Blood glucose: 200-300 (High) High.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.  The patient/reporter stated that she takes a Blood Pressure pill without specifying the name  No treatment information was provided by the reporter.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  The patient's medical history of diabetes on insulin remains a confounder for the event of hyperglycemia.   Most recent FOLLOW-UP information incorporated above includes: On 28-Jun-2021: Follow-up information was received on 28-Jun-2021 contains information regarding the reporter address details.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  The patient's medical history of diabetes on insulin remains a confounder for the event of hyperglycemia.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Muscle spasms, Muscle twitching, Nail discolouration
Clinical narrative: Cramps on inner thigh; Weakness; Breathing was rapid; Finger tips purple; Light headed; hands pulsating,clammed up; Hands sore; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of MUSCLE SPASMS (Cramps on inner thigh), ASTHENIA (Weakness), RESPIRATORY RATE INCREASED (Breathing was rapid), NAIL DISCOLOURATION (Finger tips purple) and DIZZINESS (Light headed) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced MUSCLE SPASMS (Cramps on inner thigh), ASTHENIA (Weakness), RESPIRATORY RATE INCREASED (Breathing was rapid), NAIL DISCOLOURATION (Finger tips purple), DIZZINESS (Light headed), MUSCLE TWITCHING (hands pulsating,clammed up) and PAIN IN EXTREMITY (Hands sore). At the time of the report, MUSCLE SPASMS (Cramps on inner thigh), ASTHENIA (Weakness), RESPIRATORY RATE INCREASED (Breathing was rapid), NAIL DISCOLOURATION (Finger tips purple), DIZZINESS (Light headed), MUSCLE TWITCHING (hands pulsating,clammed up) and PAIN IN EXTREMITY (Hands sore) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Respiratory rate increased
Clinical narrative: Cramps on inner thigh; Weakness; Breathing was rapid; Finger tips purple; Light headed; hands pulsating,clammed up; Hands sore; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of MUSCLE SPASMS (Cramps on inner thigh), ASTHENIA (Weakness), RESPIRATORY RATE INCREASED (Breathing was rapid), NAIL DISCOLOURATION (Finger tips purple) and DIZZINESS (Light headed) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced MUSCLE SPASMS (Cramps on inner thigh), ASTHENIA (Weakness), RESPIRATORY RATE INCREASED (Breathing was rapid), NAIL DISCOLOURATION (Finger tips purple), DIZZINESS (Light headed), MUSCLE TWITCHING (hands pulsating,clammed up) and PAIN IN EXTREMITY (Hands sore). At the time of the report, MUSCLE SPASMS (Cramps on inner thigh), ASTHENIA (Weakness), RESPIRATORY RATE INCREASED (Breathing was rapid), NAIL DISCOLOURATION (Finger tips purple), DIZZINESS (Light headed), MUSCLE TWITCHING (hands pulsating,clammed up) and PAIN IN EXTREMITY (Hands sore) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site rash
Clinical narrative: Rash (injection site); This spontaneous case was reported by a patient and describes the occurrence of INJECTION SITE RASH (Rash (injection site)) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE RASH (Rash (injection site)). At the time of the report, INJECTION SITE RASH (Rash (injection site)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.   Treatment information was not provided.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Vaccination site erythema, Vaccination site pain, Vaccination site rash, Vaccination site warmth
Clinical narrative: lighter red circle, it is around 4 inches in diameter; Vaccination site pain; red circle  around the injection site.; red circle rash  the injection site.; Swelling gland in the left arm; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE WARMTH (lighter red circle, it is around 4 inches in diameter), LYMPHADENOPATHY (Swelling gland in the left arm), VACCINATION SITE PAIN (Vaccination site pain), VACCINATION SITE ERYTHEMA (red circle  around the injection site.) and VACCINATION SITE RASH (red circle rash  the injection site.) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Jan-2021, the patient experienced LYMPHADENOPATHY (Swelling gland in the left arm). On 22-Jan-2021, the patient experienced VACCINATION SITE PAIN (Vaccination site pain), VACCINATION SITE ERYTHEMA (red circle  around the injection site.) and VACCINATION SITE RASH (red circle rash  the injection site.). On 24-Jan-2021, the patient experienced VACCINATION SITE WARMTH (lighter red circle, it is around 4 inches in diameter). At the time of the report, VACCINATION SITE WARMTH (lighter red circle, it is around 4 inches in diameter), LYMPHADENOPATHY (Swelling gland in the left arm), VACCINATION SITE PAIN (Vaccination site pain), VACCINATION SITE ERYTHEMA (red circle  around the injection site.) and VACCINATION SITE RASH (red circle rash  the injection site.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Concomitant product use was not provided by the reporter.   Treatment information was not provided.  The patient went to urgent case and was prescribed prednisone on 24-Jan-2021.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: pain in injection site; A spontaneous report was received from a consumer concerning 53-year-old, female patient, participating in the Moderna's COVID-19 vaccine (mRNA-1273) Emergency Use Program  experienced   pain in the injection site.  The patient's medical history, is not provided by the reporter  Concomitant medications were not reported.   The patient received their first of two planned dose of mRNA-1273 on 18Jan2021.The patient received their first of two planned doses of mRNA-1273 in(Lot number: 030L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.    Experienced Pain In the injection site.    No lab data is reported by the reporter.   Action taken with mRNA-1273 in response to the events was not reported.     The outcome of events, Pain on injection site is unknown .   The reporter did not provide an assessment for the events.  Since no Seriousness criteria is reported , hence the case is considered to be Non-serious.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, COVID-19, Nasal congestion, Nausea, Pain in extremity
Clinical narrative: covid-19; Runny nose; Nasal congestion; Joint pain; Nausea; arm extremely painful to touch; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (covid-19), RHINORRHOEA (Runny nose), NASAL CONGESTION (Nasal congestion), ARTHRALGIA (Joint pain) and NAUSEA (Nausea) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K02A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMINS [VITAMINS NOS] for an unknown indication.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Dec-2020, the patient experienced COVID-19 (covid-19), RHINORRHOEA (Runny nose), NASAL CONGESTION (Nasal congestion), ARTHRALGIA (Joint pain), NAUSEA (Nausea) and PAIN IN EXTREMITY (arm extremely painful to touch). On 31-Dec-2020, PAIN IN EXTREMITY (arm extremely painful to touch) had resolved. On 01-Jan-2021, RHINORRHOEA (Runny nose) had resolved. On 02-Jan-2021, ARTHRALGIA (Joint pain) had resolved. At the time of the report, COVID-19 (covid-19) outcome was unknown and NASAL CONGESTION (Nasal congestion) and NAUSEA (Nausea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. treatment  for the symptoms Tylenol. Convalescent plasma for blind study, so she doesn't known if she got the antibodies or not
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea
Clinical narrative: covid-19; Runny nose; Nasal congestion; Joint pain; Nausea; arm extremely painful to touch; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (covid-19), RHINORRHOEA (Runny nose), NASAL CONGESTION (Nasal congestion), ARTHRALGIA (Joint pain) and NAUSEA (Nausea) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K02A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMINS [VITAMINS NOS] for an unknown indication.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Dec-2020, the patient experienced COVID-19 (covid-19), RHINORRHOEA (Runny nose), NASAL CONGESTION (Nasal congestion), ARTHRALGIA (Joint pain), NAUSEA (Nausea) and PAIN IN EXTREMITY (arm extremely painful to touch). On 31-Dec-2020, PAIN IN EXTREMITY (arm extremely painful to touch) had resolved. On 01-Jan-2021, RHINORRHOEA (Runny nose) had resolved. On 02-Jan-2021, ARTHRALGIA (Joint pain) had resolved. At the time of the report, COVID-19 (covid-19) outcome was unknown and NASAL CONGESTION (Nasal congestion) and NAUSEA (Nausea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. treatment  for the symptoms Tylenol. Convalescent plasma for blind study, so she doesn't known if she got the antibodies or not
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Very achy; A Spontaneous report was received from a Consumer concerning a male patient of unknown age who received a dose of Moderna's COVID-19 vaccine (mRNA-1273) Myalgia, Pyrexia, Chills.  The patient's medical history was not provided.  No relevant concomitant medications were reported.  On 22 Jan 2021, the patient received her first of two planned doses of mRNA-1273 (lot/batch: unknown but said 20A) for prophylaxis of COVID-19 infection.  On 23 Jan 2021, the patient reports she received a dose of Moderna's COVID-19 vaccine (mRNA-1273) and experienced severe chills, fever going from 99 to 100 and back down again.  Laboratory details were not provided.  Treatment details were not provided.  Action taken with mRNA-1273 in response to the events was not reported.  On date of this report, the outcome of the events of patient receiving a dose of vaccine and experienced events Myalgia, Pyrexia, Chills were unknown/ not reported.  Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain in extremity, Vaccination complication, Vaccination site erythema
Clinical narrative: Arm was hurting; not feeling well,; Nausea; red spot vaccination site; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (Arm was hurting), VACCINATION COMPLICATION (not feeling well,), NAUSEA (Nausea) and VACCINATION SITE ERYTHEMA (red spot vaccination site) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 22-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 22-Jan-2021, the patient experienced PAIN IN EXTREMITY (Arm was hurting), VACCINATION COMPLICATION (not feeling well,), NAUSEA (Nausea) and VACCINATION SITE ERYTHEMA (red spot vaccination site).        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Inflammation, Pain in extremity, Peripheral swelling, Pruritus, Vaccination site erythema
Clinical narrative: Arm got a little sore; swollen; hot to touch; Itcyy; red wheeled; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (Arm got a little sore), VACCINATION SITE ERYTHEMA (red wheeled), PERIPHERAL SWELLING (swollen), INFLAMMATION (hot to touch) and PRURITUS (Itcyy) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Arm got a little sore), VACCINATION SITE ERYTHEMA (red wheeled), PERIPHERAL SWELLING (swollen), INFLAMMATION (hot to touch) and PRURITUS (Itcyy). The patient was treated with STEROIDS for Adverse event, at a dose of UNK dosage form. At the time of the report, PAIN IN EXTREMITY (Arm got a little sore), VACCINATION SITE ERYTHEMA (red wheeled), PERIPHERAL SWELLING (swollen), INFLAMMATION (hot to touch) and PRURITUS (Itcyy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Feeling cold, Hot flush, Hypoaesthesia, Nausea
Clinical narrative: Hot flashes; numbness; feel tired; foggy; feeling cold; Nauseous; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of HOT FLUSH (Hot flashes), HYPOAESTHESIA (numbness), VACCINATION COMPLICATION (feel tired), FEELING ABNORMAL (foggy) and FEELING COLD (feeling cold) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included OMEPRAZOLE for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced HOT FLUSH (Hot flashes), HYPOAESTHESIA (numbness), VACCINATION COMPLICATION (feel tired), FEELING ABNORMAL (foggy), FEELING COLD (feeling cold) and NAUSEA (Nauseous). The patient was treated with IBUPROFEN for Adverse event, at a dose of UNK dosage form. At the time of the report, HOT FLUSH (Hot flashes), HYPOAESTHESIA (numbness), VACCINATION COMPLICATION (feel tired), FEELING ABNORMAL (foggy), FEELING COLD (feeling cold) and NAUSEA (Nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Hot flashes; numbness; feel tired; foggy; feeling cold; Nauseous; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of HOT FLUSH (Hot flashes), HYPOAESTHESIA (numbness), VACCINATION COMPLICATION (feel tired), FEELING ABNORMAL (foggy) and FEELING COLD (feeling cold) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included OMEPRAZOLE for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced HOT FLUSH (Hot flashes), HYPOAESTHESIA (numbness), VACCINATION COMPLICATION (feel tired), FEELING ABNORMAL (foggy), FEELING COLD (feeling cold) and NAUSEA (Nauseous). The patient was treated with IBUPROFEN for Adverse event, at a dose of UNK dosage form. At the time of the report, HOT FLUSH (Hot flashes), HYPOAESTHESIA (numbness), VACCINATION COMPLICATION (feel tired), FEELING ABNORMAL (foggy), FEELING COLD (feeling cold) and NAUSEA (Nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Rash all over her body; itchy around shoulders; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash all over her body) and PRURITUS (itchy around shoulders) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Jan-2021, the patient experienced RASH (Rash all over her body) and PRURITUS (itchy around shoulders). At the time of the report, RASH (Rash all over her body) and PRURITUS (itchy around shoulders) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Chest pain, Diarrhoea, Lymphadenopathy
Clinical narrative: Chest pain; Diarrhea; lymphadenopathy; This spontaneous case was reported by a patient and describes the occurrence of CHEST PAIN (Chest pain), LYMPHADENOPATHY (lymphadenopathy) and DIARRHOEA (Diarrhea) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CHEST PAIN (Chest pain), LYMPHADENOPATHY (lymphadenopathy) and DIARRHOEA (Diarrhea). At the time of the report, CHEST PAIN (Chest pain), LYMPHADENOPATHY (lymphadenopathy) and DIARRHOEA (Diarrhea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information provided.
Sex: M
Vaccine: COVID19
Symptoms: Influenza like illness, Vaccination site pain
Clinical narrative: Flu like symptoms; Pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and VACCINATION SITE PAIN (Pain at injection site) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 and Prostate cancer (Stage 1). Concomitant products included SILODOSIN for Prostate cancer.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and VACCINATION SITE PAIN (Pain at injection site). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for Adverse event, at a dose of UNK dosage form. On 16-Jan-2021, INFLUENZA LIKE ILLNESS (Flu like symptoms) outcome was unknown and VACCINATION SITE PAIN (Pain at injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Peripheral swelling, Pyrexia
Clinical narrative: Arm very swollen; arm red and hot; fever in night; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Arm very swollen), FEELING HOT (arm red and hot) and PYREXIA (fever in night) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Arm very swollen), FEELING HOT (arm red and hot) and PYREXIA (fever in night). At the time of the report, PERIPHERAL SWELLING (Arm very swollen), FEELING HOT (arm red and hot) and PYREXIA (fever in night) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pruritus, Injection site warmth
Clinical narrative: Blotchy redness around the injection site; itchy; warm to touch; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE ERYTHEMA (Blotchy redness around the injection site), INJECTION SITE PRURITUS (itchy) and INJECTION SITE WARMTH (warm to touch) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced INJECTION SITE ERYTHEMA (Blotchy redness around the injection site), INJECTION SITE PRURITUS (itchy) and INJECTION SITE WARMTH (warm to touch). At the time of the report, INJECTION SITE ERYTHEMA (Blotchy redness around the injection site), INJECTION SITE PRURITUS (itchy) and INJECTION SITE WARMTH (warm to touch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information included ice.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Urticaria
Clinical narrative: hives in all of her body; itchy in a spot in her neck; This spontaneous case was reported by a pharmacist and describes the occurrence of URTICARIA (hives in all of her body) and PRURITUS (itchy in a spot in her neck) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concomitant products included LISINOPRIL, ATORVASTATIN, BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT), LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) and VITAMINS NOS for an unknown indication.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-1902, the patient experienced PRURITUS (itchy in a spot in her neck). On 14-Jan-2021, the patient experienced URTICARIA (hives in all of her body). The patient was treated with METHYLPREDNISOLONE for Urticaria, at a dose of UNK dosage form and FAMOTIDINE (PEPCID [FAMOTIDINE]) at a dose of UNK dosage form. On 20-Jan-2021, URTICARIA (hives in all of her body) had resolved. At the time of the report, PRURITUS (itchy in a spot in her neck) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Alpha 1 foetoprotein increased, Exposure during pregnancy, Pregnancy test, Scan, Ultrasound scan
Clinical narrative: 27 weeks pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (27 weeks pregnant) in a 36-year-old female patient (gravida 5, para 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     The patient's past medical history included Pregnancy on 21-Feb-2017. Concurrent medical conditions included Allergy (Codeine Allergy). Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for an unknown indication.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. The patient's last menstrual period was on 04-Aug-2020 and the estimated date of delivery was 14-May-2021. On 12-Feb-2021, the patient experienced EXPOSURE DURING PREGNANCY (27 weeks pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-seventh week of the pregnancy.  On 12-Feb-2021, EXPOSURE DURING PREGNANCY (27 weeks pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Sep-2020, Pregnancy test: positive (Positive) positive pregnancy test. On 22-Nov-2020, Ultrasound scan: normal (normal) nuchal ultrasound. On 02-Dec-2020, Alpha 1 foetoprotein increased: normal (normal) Alpha fetal protein panel-normal. On 29-Dec-2020, Scan: normal (normal) 20 week anatomy scan.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No treatment details were reported.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling
Clinical narrative: itchy at injection site; swelling at injection site; redness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PRURITUS (itchy at injection site), INJECTION SITE SWELLING (swelling at injection site) and INJECTION SITE ERYTHEMA (redness at the injection site) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Cholesterol. Concomitant products included VITAMINS NOS for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021, the patient experienced INJECTION SITE PRURITUS (itchy at injection site), INJECTION SITE SWELLING (swelling at injection site) and INJECTION SITE ERYTHEMA (redness at the injection site). On 18-Jan-2021, INJECTION SITE PRURITUS (itchy at injection site) had resolved. At the time of the report, INJECTION SITE SWELLING (swelling at injection site) and INJECTION SITE ERYTHEMA (redness at the injection site) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Feeling hot, Pruritus, Swelling
Clinical narrative: warm to touch; Redness; swelling; itching; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Redness), SWELLING (swelling), PRURITUS (itching) and FEELING HOT (warm to touch) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced ERYTHEMA (Redness), SWELLING (swelling) and PRURITUS (itching). On an unknown date, the patient experienced FEELING HOT (warm to touch). The patient was treated with FEXOFENADINE HYDROCHLORIDE (ALLEGRA) at an unspecified dose and frequency; CEFRADINE (VICODINE) at an unspecified dose and frequency; VITAMIN D NOS at an unspecified dose and frequency and MULTIVITAMIN [VITAMINS NOS] at an unspecified dose and frequency. At the time of the report, ERYTHEMA (Redness), SWELLING (swelling), PRURITUS (itching) and FEELING HOT (warm to touch) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jan-2021: NNI
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site induration, Vaccination site reaction, Vaccination site urticaria
Clinical narrative: A mild local reaction; Mild induration; Urticaria; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE REACTION (A mild local reaction), VACCINATION SITE INDURATION (Mild induration) and VACCINATION SITE URTICARIA (Urticaria) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE REACTION (A mild local reaction), VACCINATION SITE INDURATION (Mild induration) and VACCINATION SITE URTICARIA (Urticaria). On 25-Jan-2021, VACCINATION SITE REACTION (A mild local reaction), VACCINATION SITE INDURATION (Mild induration) and VACCINATION SITE URTICARIA (Urticaria) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jan-2021: No specific follow-up information recorded.